Chronic Passive Heating in Individuals With T2DM
The Effect of Chronic Passive Heating on Insulin Sensitivity and Cardiovascular Function in People With Type 2 Diabetes Mellitus: A Pre- and Post-test Trial
1 other identifier
interventional
17
1 country
1
Brief Summary
Type 2 diabetes mellitus (T2DM) is a metabolic condition characterized by chronic hyperglycemia and progressive insulin resistance, which progressively lead to macro- and microvascular damage and subsequent impairments in blood pressure (BP) control. Therapeutic approaches to manage T2DM focus on improving glycaemic control and BP and include pharmaceutical treatments (e.g. Metformin and insulin), physical activity and exercise, and calorie restriction. However, pharmaceutical interventions can be expensive and are associated with low adherence. Although exercise and diet programs have been shown to be effective, like pharmaceutical interventions, they often have poor adherence in people with T2DM. With the number of people with T2DM (464 million) continuing to rise and expected to reach 700 million by 2045, the costs associated with the clinical management of this condition are likely to become unsustainable. There is, therefore, a need to explore the potential of alternative interventions. In particular, interventions which may be cheaper than clinical management and have better adherence than exercise, and hypoglycemic agents, to improve glycemic control and deleterious cardiovascular manifestations of this condition. Passive heating may be one such intervention with therapeutic potential.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 14, 2021
CompletedFirst Posted
Study publicly available on registry
April 26, 2021
CompletedStudy Start
First participant enrolled
May 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 19, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 19, 2022
CompletedResults Posted
Study results publicly available
January 3, 2025
CompletedJanuary 3, 2025
November 1, 2024
1.6 years
April 14, 2021
April 7, 2024
November 13, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Insulin Sensitivity
Does chronic passive heating improve insulin sensitivity? Calculated using the QUICKI for fasting and Gutt for post-prandial, with glucose and insulin concentrations. A higher value means they have better insulin sensitivity.
Change from pre (day 1) - post 8-12 days of 1 hour of passive heating
Secondary Outcomes (16)
Plasma Glucose Concentration
pre - post following 8-12 days of 1 hour of passive heating
Plasma eHSP70 Concentration
pre - post following 8-12 days of 1 hour of passive heating
Plasma IL-6 Concentration
pre - post following 8-12 days of 1 hour of passive heating
Plasma IL-10 Concentration
pre - post following 8-12 days of 1 hour of passive heating
Resting Metabolic Rate
pre - post following 8-12 days of 1 hour of passive heating
- +11 more secondary outcomes
Study Arms (1)
Passive heating
EXPERIMENTAL8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
Interventions
8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
Eligibility Criteria
You may qualify if:
- Male or female (post-menopausal) aged 35 years or above.
- Diagnosed with T2DM as defined by the WHO (≥48 mmol/mol).
- Participant is willing and able to give informed consent for participation in the study.
- Participant is able to understand and fully cooperate with the study protocol.
You may not qualify if:
- Severe peripheral neuropathy (to the point to which they cannot sense temperature)
- Uncontrolled hypertension (≥180 systolic / 100 diastolic mmHg)
- Taking any medication which may interfere with data interpretation or safety
- Who have had a myocardial infarction or cerebro-vascular event
- Any cardiac abnormalities which restrict hard exercise
- Current smokers or who have stopped within 3 months
- Participant is unable to understand and/or fully cooperate with the study protocol
- Any other serious medical condition which would interfere with data interpretation or safety will be excluded from participation.
- Skin ulcerations
- Eczema
- Pre-existing postural hypertension
- Existing cardiac diseases (identified during screening)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Portsmouthlead
- Portsmouth Hospitals NHS Trustcollaborator
Study Sites (1)
Department of Sport and Exercise Science
Portsmouth, Hampshire, PO1 2ER, United Kingdom
Results Point of Contact
- Title
- Dr Anthony Shepherd
- Organization
- University of Portsmouth
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator, Senior Lecturer in Physical Activity, Exercise and Health
Study Record Dates
First Submitted
April 14, 2021
First Posted
April 26, 2021
Study Start
May 24, 2021
Primary Completion
December 19, 2022
Study Completion
December 19, 2022
Last Updated
January 3, 2025
Results First Posted
January 3, 2025
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share
There is no plan to release IPD, until all avenues of further funding have been exhausted.